8-bromocyclic GMP

Also Known As:

8-Br-cyclic GMP; 8-bromo cGMP; 8-bromo-cGMP; 8-bromo-cyclic GMP; 8-bromocyclic GMP, sodium salt; 8-bromocyclic guanosine monophosphate; 8-bromoguanosine 3',5'-cyclic monophosphate; 8-bromoguanosine 3',5'-monophosphate; Br CGMP; Rp-8-Br-cGMP; 8-bromoguanosine, cyclic 3',5'-(hydrogen phosphate)

Networked: 60 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Graham, Charles H: 3 articles (01/2020 - 09/2002)
2.	Raj, J Usha: 3 articles (03/2012 - 09/2003)
3.	Siemens, D Robert: 2 articles (01/2020 - 04/2007)
4.	Gao, Yuansheng: 2 articles (10/2007 - 09/2003)
5.	Adams, Michael A: 2 articles (04/2007 - 09/2002)
6.	Etgen, Anne M: 2 articles (12/2004 - 03/2002)
7.	Barsoum, Ivraym B: 1 article (01/2020)
8.	Kim, Judy: 1 article (01/2020)
9.	Loh, Harrison: 1 article (01/2020)
10.	Paré, Jean-François: 1 article (01/2020)

Related Diseases

1.	Ischemia 11/01/1998 - "Preservation with 8-bromo-cyclic GMP improves pulmonary function after prolonged ischemia." 07/01/1993 - "Addition of the permeable analogue of guanosine 3',5'-cyclic monophosphate, 8-bromoguanosine 3',5'-cyclic monophosphate, improved reperfusion-induced intestinal blood flow significantly but did not provide protection against mucosal barrier disruption associated with the first hour of ischemia-reperfusion. " 10/01/1999 - "The pretreatment of ischemic rats with 8-bromo-cGMP (16 mg/kg i.v. 30 min before ischemia) or with L-arginine (the endogenous precursor of NO, 100 mg/kg i.v.) significantly diminished the ischemia-reperfusion-induced release of all these enzymes. " 12/01/1999 - "Cell shortening data were acquired at: (i) baseline followed by 8-Bromo-cGMP 10(-6) M (8-Br-cGMP) and then KT 5823 10(-6) M (cyclic GMP protein kinase inhibitor) and (ii) simulated ischemia (20 min of 95% N(2)-5% CO(2) at 37 degrees C) followed by simulated reperfusion (reoxygenation) with addition of 8-Br-cGMP 10(-6) M followed by KT 5823 10(-6) M, (iii) addition of 8-Br-cGMP prior to ischemia followed by the addition of KT 5823 10(-6) M after 30 min of reoxygenation. "
2.	Hypercholesterolemia 12/01/2006 - "The reduction in RBC deformability associated with hypercholesterolemia was significantly improved during incubation with each of three different NO pathway activators: a NO donor, 8-bromo-cyclic GMP, and arginine; however, no additional reduction was observed with ADMA administration. "
3.	Hypoxia (Hypoxemia) 03/01/2018 - "Concomitantly, the HO-1 byproduct CO and the cGMP analogue 8-bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP) increased MKP-5 expression, and pretreatment with CO and 8-Br-cGMP inhibited hypoxia-induced HIF-1α and ET-1 expression. " 09/01/2003 - "8-Bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP), a cell membrane-permeable analog of cGMP, induced a greater relaxation in vessels incubated in normoxia than in hypoxia. " 02/01/2003 - "Both VNP (10(-7) mol/L) and 8-Bromo-cGMP (10(-3) mol/L) decreased MTT A490 nm value in cardiac fibroblast (P < 0.05 vs hypoxia group). " 02/01/2003 - "The cultured cardiac fibroblasts were divided randomly into four groups: control group, hypoxia group, hypoxia + VNP group and hypoxia + 8-Bromo-cGMP group. " 07/09/1984 - "8-bromo-cGMP abolished these hypoxia-induced changes. "
4.	Contracture 12/01/1995 - "5. High K+ (85 mmol l-1)-induced contracture in rat heart muscle was reduced by 8-Br-cyclic GMP but not by SIN-1. " 02/01/2006 - "8-Bromo-cGMP, a membrane-permeable cGMP analogue, reduced the potentiating effect of proctolin on muscle contracture. " 01/01/1984 - "In the muscle depolarized by 540 mM KCl + 5 mM EGTA solution, 8-bromo-cyclic GMP could not relax Ca-contracture. "
5.	Hyperoxia 09/01/2011 - "The abnormal vascular development caused by hyperoxia was reverted by pharmacological treatments that increased cGMP levels, such as 8-bromo-cGMP or 4-{[3',4'-(methylenedioxy)benzyl]amino}-6-methoxyquinazoline, a specific inhibitor of PDE5. " 08/31/2012 - "Prior work has shown that hyperoxia causes S-nitrosylated actin (SNO-actin) formation, which mediates β(2) integrin dysfunction, and these changes can be reversed by formylmethionylleucylphenylalanine or 8-bromo-cyclic GMP. "

Related Drugs and Biologics

1.	Arginine (L-Arginine)
2.	Guanosine
3.	Nitroprusside (Sodium Nitroprusside)
4.	Cyclic GMP
5.	Atrial Natriuretic Factor (ANF)
6.	NG-Nitroarginine Methyl Ester (L-NAME)
7.	KT 5823
8.	S-Nitroso-N-Acetylpenicillamine
9.	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)
10.	8-Bromo Cyclic Adenosine Monophosphate (8 Bromo Cyclic Adenosine Monophosphate)

Related Therapies and Procedures

1.	Intraventricular Infusions
2.	Punctures
3.	Denervation